Opendata, web and dolomites

PD-MitoQUANT SIGNED

PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PD-MitoQUANT" data sheet

The following table provides information about the project.

Coordinator
ROYAL COLLEGE OF SURGEONS IN IRELAND 

Organization address
address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2
website: www.rcsi.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 6˙882˙315 €
 EC max contribution 4˙497˙935 € (65%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) coordinator 1˙095˙123.00
2    INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE FR (PARIS) participant 855˙375.00
3    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 544˙635.00
4    DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV DE (BONN) participant 541˙118.00
5    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 403˙885.00
6    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 360˙587.00
7    MIMETAS BV NL (Leiden) participant 250˙835.00
8    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 160˙000.00
9    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 148˙875.00
10    PINTAIL LTD IE (Blackrock) participant 137˙500.00
11    H. LUNDBECK AS DK (VALBY) participant 0.00
12    PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG UK (LONDON) participant 0.00
13    TEVA PHARMACEUTICAL INDUSTRIES LIMITED IL (PETACH TIVKA) participant 0.00
14    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is lacking. Through provision of quantitative and systematic characterisation of mitochondrial dysfunction, PD-MitoQUANT will provide unprecedented understanding of the role of mitochondrial dysfunction in PD, identify and validate novel disease biomarkers, and propose innovative therapeutic targets that can be further progressed by the EFPIA partners. The consortium leverages multi-disciplinary expertise in the fields of αSyn biochemistry, iPSC-derived PD models, mitochondrial function and structural analysis, proteotoxicity, ER stress and UPR signaling, systems biology of mitochondrial function, and in vivo animal models. A key focus will be quantitative description and integrated analysis of mitochondrial function and its relation to proteotoxicity; representing a key panel of consortium partners Prehn [RCSI], Abramov [UCL], Corti [ICM] and Koopmann [RUMC] who also have assembled long–standing expertise in primary neuron culture, iPSC-derived neurons, PD in vivo models, proteostasis and ageing studies. These investigations will be supported by expert teams in iPSC-derived in vitro PD models and in vivo PD models from the academic partners (Hunot [ICM], Melki [CNRS], Di Monte [DZNE], Broccoli [CNR], SME [Mimetas] and EFPIA partners [Teva], [Lundbeck] and [UCB]. Through integrated in vitro, in silico and in vivo approaches, and supported computationally by SME [GENEXPLAIN], PD-MitoQUANT will perform thorough and unprecedented investigations of mitochondrial dysfunction. Finally, the consortium will initiate a European research platform of excellence investigating mitochondrial dysfunction in PD continuing beyond the project, further supported by [PUK]’s PD human tissue biobank. This will provide long-term and sustainable progress in the understanding of mitochondrial dysfunction in PD and towards clinical application.

 Publications

year authors and title journal last update
List of publications.
2020 Josquin Courte, Luc Bousset, Ysander Von Boxberg, Catherine Villard, Ronald Melki, Jean-Michel Peyrin
The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-020-61757-x
Scientific Reports 10/1 2020-04-01
2020 Amulya Nidhi Shrivastava, Luc Bousset, Marianne Renner, Virginie Redeker, Jimmy Savistchenko, Antoine Triller, Ronald Melki
Differential Membrane Binding and Seeding of Distinct α-Synuclein Fibrillar Polymorphs
published pages: , ISSN: 0006-3495, DOI: 10.1016/j.bpj.2020.01.022
Biophysical Journal 27 January 2020 2020-03-23
2019 Nolwen L. Rey, Luc Bousset, Sonia George, Zachary Madaj, Lindsay Meyerdirk, Emily Schulz, Jennifer A. Steiner, Ronald Melki, Patrik Brundin
α-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb
published pages: 1-18, ISSN: 2051-5960, DOI: 10.1186/s40478-019-0859-3
Acta Neuropathologica Communications 7/1 2020-03-19
2019 M. Jacoupy, E. Hamon-Keromen, A. Ordureau, Z. Erpapazoglou, F. Coge, J.-C. Corvol, O. Nosjean, C. Mannoury la Cour, M. J. Millan, J. A. Boutin, J. W. Harper, A. Brice, D. Guedin, C. A. Gautier, O. Corti
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells
published pages: 1-15, ISSN: 2045-2322, DOI: 10.1038/s41598-019-47352-9
Scientific Reports 9/1 2020-03-19
2019 Parvez Alam, Luc Bousset, Ronald Melki, Daniel E. Otzen
α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities
published pages: , ISSN: 0022-3042, DOI: 10.1111/jnc.14808
Journal of Neurochemistry 2020-03-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PD-MITOQUANT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PD-MITOQUANT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More